Coronavirus channel feed

Covid-19 roundup: J&J plans 60,000-per­son PhI­II for Sep­tem­ber; Pe­ter Marks draws a red line

5 years ago

Covid-19 roundup: Pfiz­er/BioN­Tech spell out PhI­II pri­or­i­ty; Le­gal ex­perts urge FDA to re­frain from vac­cine EUAs

5 years ago

Sor­ren­to ousts CFO as long-run­ning Covid-19 dra­ma con­tin­ues

5 years ago
People

Covid-19 roundup: Fau­ci, Collins in­ter­vene to stop FDA plas­ma au­tho­riza­tion, cit­ing weak da­ta; Roche, Re­gen­eron try to take an­ti­bod­ies glob­al

5 years ago
Deals

Covid-19 roundup: In­side CTAP: 270 tri­als un­der­way, 570+ in the FDA line; WHO chief calls out 'vac­cine na­tion­al­is­m'

5 years ago

Covid-19 roundup: Just how much is the ‘first wave’ mar­ket for Covid-19 vac­cines worth? One top an­a­lyst sets the prize at $20B

5 years ago

US gov­ern­ment re­port­ed­ly be­gins prepar­ing for Covid-19 chal­lenge tri­als. Are they eth­i­cal?

5 years ago
R&D

Covid-19 roundup: As­traZeneca signs 400M vac­cine sup­ply deal with EU; Sinopharm re­ports pos­i­tive Phase I/II da­ta for vac­cine can­di­date

5 years ago

Covid-19 roundup: Sor­ren­to threat­ens to sue crit­ic of their coro­n­avirus ‘cure’; No­vavax signs with SK bio­science

5 years ago

Covid-19 roundup: Re­searchers call out Gilead for di­ver­si­ty of remde­sivir tri­als in NE­JM; Mex­i­co in vac­cine dose, tri­al talks

5 years ago

Mod­er­na of­fers steep dis­count in US sup­ply deal — but still takes the crown with close to $2.5B in vac­cine con­tracts

5 years ago

End­points News ranks the top 57 play­ers in the Covid-19 vac­cine race. Here's how it stacks up to­day

5 years ago
In Focus

Covid-19 roundup: Pfiz­er-backed BioN­Tech plans to seek FDA OK for a new vac­cine 'as ear­ly as' Oc­to­ber — ahead of the elec­tion

5 years ago

Covid-19 roundup: Cure­Vac beefs up its uni­corn IPO dreams as bil­lion­aire own­er takes this Covid-19 mR­NA play­er on a forced march to Nas­daq; Ko­dak's $765M deal is put on hold

5 years ago
Outsourcing
Pharma

When will it end? Big Phar­ma's top vac­cine ex­pert at OWS of­fers a speedy time­line for a Covid-19 vac­cine — ei­ther be­fore or right af­ter the elec­tion

5 years ago
R&D

Covid-19 roundup: Gates Foun­da­tion pours $150M in­to In­dia’s Serum In­sti­tute; Pfiz­er teams with Gilead on remde­sivir

5 years ago

'Oc­to­ber is com­ing,' and every­one still wants to know if a Covid-19 vac­cine will be whisked through the FDA ahead of the elec­tion

5 years ago
Bioregnum
Opinion

Covid-19 roundup: 34 AGs call for ‘march-in’ rights on remde­sivir; Hahn pleads with pub­lic to trust FDA's vac­cine re­view

5 years ago

Mod­er­na CEO Stéphane Ban­cel out­lines a prospec­tive moth­er­lode of Covid-19 vac­cine rev­enue — will a back­lash fol­low?

5 years ago

Covid-19 roundup: J&J and BAR­DA agree to $1 bil­lion for 100 mil­lion dos­es; Plas­ma re­duces mor­tal­i­ty by 50% — re­ports

5 years ago

FDA touts ad­vanced man­u­fac­tur­ing to ad­dress Covid-19 short­falls

5 years ago
FDA+

No­vavax her­alds the lat­est pos­i­tive snap­shot of ear­ly-stage Covid-19 vac­cine — so why did its stock briefly crater?

5 years ago

Covid-19 roundup: FDA com­mis­sion­ers call for more ‘con­cert­ed ef­fort’ on con­va­les­cent plas­ma R&D; Re­gen­eron boosts case for an­ti­body cock­tail with new an­i­mal da­ta

5 years ago

OWS' Mon­cef Slaoui lam­basts ‘in­sult­ing’ me­dia cov­er­age: 'How are you help­ing in this pan­dem­ic?'

5 years ago
First page Previous page 45464748495051 Next page Last page
A service from the Financial Times